CapsoVision NASDAQ: CV reported steady first-quarter revenue and said it continues to advance artificial intelligence and capsule endoscopy programs aimed at expanding the use of its gastrointestinal imaging platform.
CapsoVision, Inc. (CV) Q1 2026 Earnings Call Transcript
CapsoVision, Inc. (CV) Q4 2025 Earnings Call Transcript
CV seeks FDA clearance to add AI-based reading to CapsoCam Plus to boost diagnostic accuracy and streamline reviews.